» Articles » PMID: 8842419

Neuroprotective Properties of a Protein Kinase Inhibitor Against Ischaemia-induced Neuronal Damage in Rats and Gerbils

Overview
Journal Br J Pharmacol
Publisher Wiley
Specialty Pharmacology
Date 1996 Aug 1
PMID 8842419
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

1. The neuroprotective properties of fasudil (HA1077), a novel protein kinase inhibitor, were evaluated in two animal models of cerebral ischaemia: transient bilateral carotid artery occlusion in Mongolian gerbils and cerebral microembolization in rats. 2. The cytoprotective effect of fasudil on delayed neuronal death in gerbils was compared with the effects of nimodipine, a calcium channel antagonist and ozagrel, a thromboxane A2 synthetase inhibitor. The average of the neuronal cell density in the ischaemic control group was 17.8 +/- 2.1 cells mm-1, whereas fasudil (30 mg kg-1) significantly diminished the loss of CA1 neurones with the average of the neuronal cell density of 101.0 +/- 22.0 cells mm-1; nimodipine (10 mg kg-1) and ozagrel (30 mg kg-1) did not significantly protect against the ischaemia-induced neuronal loss. 3. In the rat model, the effects of fasudil on the histological and neurological consequences of cerebral microembolization produced via the injection of microspheres were examined. Twenty-four hours after the injection of microspheres into the internal carotid artery, all animals in the control group showed typical symptoms of stroke. Neurological function was significantly improved in the fasudil-treated animals. In the controls, the infarcted area in a cortical slice selected to include the hippocampal area was 0.25 +/- 0.01 cm2 (mean +/- s.e.mean) (43.9 +/- 2.4% of cortical section of the half hemisphere); the difference was significant compared to the mean area of 32.7 +/- 2.8 and 21.5 +/- 4.8% observed in rats treated with fasudil (3, 10 mg kg-1), respectively. Fasudil (10 mg kg-1) significantly suppressed the increased water content in ischaemic brain tissues (saline-treated rats, 82.4 +/- 0.2% vs fasudil-treated rats, 81.0 +/- 0.4%). 4. These results suggest that: (i) various protein kinases are involved in the pathogenesis of ischaemic injury; and (ii) the inhibition of protein kinases may be efficacious in preventing neuronal death, thus improving neurological function in the brain damage associated with ischaemic stroke.

Citing Articles

The potential role of RhoA/ROCK-inhibition on locomotor recovery after spinal cord injury: a systematic review of in-vivo studies.

Khavandegar A, Ahmadi N, Mousavi M, Ramezani Z, Khodadoust E, Hasan Zadeh Tabatabaei M Spinal Cord. 2025; 63(3):95-126.

PMID: 39956860 DOI: 10.1038/s41393-025-01064-2.


Fasudil hydrochloride and ozagrel sodium combination therapy for patients with aneurysmal subarachnoid hemorrhage: a cross-sectional study using a nationwide inpatient database.

Magara H, Tani T, Imai S, Kiyomi A, Fushimi K, Sugiura M J Pharm Health Care Sci. 2024; 10(1):49.

PMID: 39138543 PMC: 11321058. DOI: 10.1186/s40780-024-00370-w.


The novel ROCK2 selective inhibitor NRL-1049 preserves the blood-brain barrier after acute injury.

Mulder I, Abbinanti M, Woller S, Ruschel J, Coutinho J, de Vries H J Cereb Blood Flow Metab. 2024; 44(11):1238-1252.

PMID: 38833563 PMC: 11542141. DOI: 10.1177/0271678X241238845.


Effect of the ROCK inhibitor fasudil on the brain proteomic profile in the tau transgenic mouse model of Alzheimer's disease.

Collu R, Yin Z, Giunti E, Daley S, Chen M, Morin P Front Aging Neurosci. 2024; 16:1323563.

PMID: 38440100 PMC: 10911083. DOI: 10.3389/fnagi.2024.1323563.


Neurodegenerative Disease Associated Pathways in the Brains of Triple Transgenic Alzheimer's Model Mice Are Reversed Following Two Weeks of Peripheral Administration of Fasudil.

Killick R, Elliott C, Ribe E, Broadstock M, Ballard C, Aarsland D Int J Mol Sci. 2023; 24(13).

PMID: 37446396 PMC: 10342807. DOI: 10.3390/ijms241311219.


References
1.
Tsuchiya M, Sako K, Yonemasu Y, Asano T . The effects of HA1077, a novel protein kinase inhibitor, on reductions of cerebral blood flow and glucose metabolism following acute and/or chronic bilateral carotid artery ligation in Wistar rats. Exp Brain Res. 1993; 97(2):233-8. DOI: 10.1007/BF00228692. View

2.
Germano I, Bartkowski H, CASSEL M, Pitts L . The therapeutic value of nimodipine in experimental focal cerebral ischemia. Neurological outcome and histopathological findings. J Neurosurg. 1987; 67(1):81-7. DOI: 10.3171/jns.1987.67.1.0081. View

3.
Asano T, Ikegaki I, Satoh S, Suzuki Y, Shibuya M, Takayasu M . Mechanism of action of a novel antivasospasm drug, HA1077. J Pharmacol Exp Ther. 1987; 241(3):1033-40. View

4.
Alps B, Calder C, Hass W, Wilson A . Comparative protective effects of nicardipine, flunarizine, lidoflazine and nimodipine against ischaemic injury in the hippocampus of the Mongolian gerbil. Br J Pharmacol. 1988; 93(4):877-83. PMC: 1853888. DOI: 10.1111/j.1476-5381.1988.tb11475.x. View

5.
Suzuki Y, Shibuya M, Takayasu M, Asano T, Ikegaki I, Satoh S . Protein kinase activity in canine basilar arteries after subarachnoid hemorrhage. Neurosurgery. 1988; 22(6 Pt 1):1028-31. DOI: 10.1227/00006123-198806010-00009. View